French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

The French government will need guarantees that production of Doliprane will stay in France to allow the sale of the Sanofi's consumer health branch to go ahead, economy minister Antoine Armand ...

The breakthrough came after the investment group provided France with guarantees on maintaining jobs and production in the country following the talks between Sanofi, CD&R and the government ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. France is taking a small stake in Sanofi’s consumer healthcare business in order to quell a political ...

(Bloomberg) -- After a year-long takeover battle for the owner of France’s best-selling painkiller, Sanofi’s decision to sell its over-the-counter business to a US buyout firm descended into ...

Sanofi will invest more than €1 billion ($1.08 billion) in new bioproduction capacity at three manufacturing sites in France as part of a €3.5 billion programme in the country. The latest ...

Sanofi said it is the third-largest business worldwide in the market for over-the-counter medicines, vitamins and supplements. CD&R -- which has a battery of investments in France -- would help ...

Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Sanofi said last week it had entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S ...

Sanofi, France's biggest pharmaceutical group, said last week that it was in talks with CD&R for the sale of a 50% controlling stake in Opella, triggering criticism from government opponents over the ...